Zum Inhalt springen

Anixa Biosciences Unveils Phase 2 Study Plan for Breast Cancer Vaccine

Anixa Biosciences, Inc. („Anixa“ or the „Company“) (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced its strategic plan for a Phase 2 study for its breast cancer vaccine. The Phase 1 trial is being conducted at Cleveland Clinic, funded by a grant from the U.S. Department of Defense. The proposed Phase 2 trial will evaluate the efficacy of the vaccine administered in the neoadjuvant (before surgery) setting, in combination with chemotherapy and Keytruda (pembrolizumab). The goal of neoadjuvant therapy is to reduce tumor burden and to prevent tumor recurrence with the intent to improve survival. This clinical trial approach allows Anixa to enroll a broader range of patients, encompassing multiple types of breast cancer.

B. Braun Medical Receives FDA Clearance for Introcan Safety® 2 Deep Access IV Catheter

B. Braun Medical Inc. (B. Braun), a leader in smart infusion therapy and pain management, announced today that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for the Introcan Safety® 2 Deep Access IV Catheter, the newest addition to the Introcan Safety 2 IV Catheter portfolio. The Introcan Safety 2 Deep Access IV Catheter merges the trusted technologies of the original Introcan Safety 2 Multi-Access and Introcan Safety Deep Access Catheters, offering clinicians an advanced solution that combines the strengths of both devices. This innovative catheter provides fully automatic passive safety needlestick protection and multi-access blood control in longer lengths and is designed to access deeper veins in patients with difficult vascular access and to achieve longer dwell times.

U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer’s

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) („NeuroSense“), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced the issuance of a pivotal patent by the United States Patent and Trademark Office (USPTO). The newly granted patent, entitled „Compositions comprising Ciprofloxacin and Celecoxib“ (US Patent No. US 12,097,185), relates to the novel formulation of PrimeC, NeuroSense’s leading drug candidate for the treatment of Amyotrophic Lateral Sclerosis (ALS). This patent is expected to extend PrimeC’s patent  protection by an additional four years, until 2042. PrimeC is composed of ciprofloxacin and celecoxib, two FDA-approved compounds in unique doses, formulated in a technology of slow release to synchronize their pharmacokinetic (PK) profiles and enhance their therapeutic synergy. This innovative approach is designed to optimize the treatment efficacy in slowing ALS progression. The patent grant follows NeuroSense’s recent clinical findings, where PrimeC… 

more »U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer’s

Yale cellular biologist named among most inspiring scientists

Yale School of Medicine (YSM) developmental biologist Dr. Valentina Greco has been named one of Cell Press’s „50 Scientists that Inspire.“ Cell Press curated the list as part of its 50th anniversary celebration. Greco is the Carolyn Walch Slayman Professor of Genetics and professor of cell biology and dermatology at YSM, a member of Yale Cancer Center and the Yale Stem Cell Center, and co-chair of the Status of Women in Medicine. She is president-elect of the International Society for Stem Cell Research.

Curious immune cells caught between worlds

Our immune system spans two worlds—innate and adaptive. Innate immune cells are like troops at the gate ready to hold off invaders and raise the body’s alarms. Adaptive immune cells are specialists that take longer to respond but can fight off foes in a more targeted manner. Curiously, there are also immune cells that exist between worlds. Important among these cellular combatants are innate-like T cells. Their hybrid-like nature makes them promising candidates for developing new kinds of immunotherapies against diseases such as cancer. The problem is that scientists still don’t know much about how this unique type of T cell functions and develops in humans. Cold Spring Harbor Laboratory (CSHL) Assistant Professor Hannah Meyer and her collaborator at the University of Colorado Anschutz, Professor Laurent Gapin, set out to determine just that. „Studying the development of the immune system… 

more »Curious immune cells caught between worlds

Fzata, Inc. Announces Multi-million Dollar NIH Grant

Fzata, Inc. is pleased to announce a five-year UG3/UH3 non-dilutive grant (UG3NS135350) of up to $7 million, plus in-kind contributions, awarded by the NIH National Institute of Neurological Disorders and Stroke (NINDS). Grant participants include Fzata and the University of Maryland, Baltimore (UMB). The grant supports development of BioPYM™ drug candidate FZ006 as a safe and effective oral treatment for chronic visceral pain associated with inflammatory bowel syndrome (IBS). Work under the grant will include IND-enabling studies, GLP toxicology, cGMP manufacturing, phase 1 trial design, IND submission, and Phase 1a clinical trial.

Use of generative AI in application preparation and assessment

UK Research and Innovation (UKRI) launches its policy on the use of generative artificial intelligence (AI) during the funding application and assessment process. Generative AI Generative AI is a broad label used to describe any AI that can be used to create new content such as text, images, video, audio or code. It is a fast emerging and evolving technology that can present opportunities and bring benefits in the context of research and innovation by: facilitating creativity and the development of ideasproviding a useful tool for people who have neurodivergenciesreducing language barriersGenerative AI also presents potential risks for research and innovation which can compromise the integrity of the application and assessment process. Integrity is critical to upholding the values of honesty, rigour, transparency and open communication within our research and innovation system. The research and innovation community are motivated by… 

more »Use of generative AI in application preparation and assessment

Ryvu Therapeutics to present ONCO Prime platform

View in Browser Get Custom Content for Your Website or Blog Enhance your website’s or blog’s content with PR Newswire’s customized real-time news feeds. Whether you have a general information portal, or a blog dedicated to a niche audience, we can build a news feed to match your content needs. You can provide your visitors with fresh news targeted to their interests distributed directly from a trusted news source. Learn more News From Ryvu TherapeuticsTransmitted by PR Newswire for Journalists on September 23, 2024 10:31 AM EDT Ryvu Therapeutics to present ONCO Prime platform at the 6th Annual RAS-Targeted Drug Development Summit ONCO Prime is a cutting-edge drug discovery platform identifying novel synthetic lethal targets using patient-derived primary cell cultures. Initial data have identified potentially novel drug targets in KRAS-mutant colorectal cancer (CRC), and the platform has broad applicability across… 

more »Ryvu Therapeutics to present ONCO Prime platform

Finanzieller Druck auf Kranken- und Pflegekassen steigt enorm

Der BKK Landesverband Bayern rechnet für die Jahre 2024 und 2025 mit steigenden Defiziten sowohl in der Gesetzlichen Krankenversicherung (GKV) als auch in der Sozialen Pflegeversicherung (SPV). Treiber dieser Entwicklung sind ungebremste Ausgabenzuwächse und die zunehmende Belastung der Versicherten durch versicherungsfremde Leistungen. Ein großer Teil des Defizits in GKV und SPV entfällt auf versicherungsfremde Leistungen. Allein in der Pflegeversicherung belaufen sich diese auf 5,5 Mrd. Euro pro Jahr. Davon entfallen allein 3,5 Mrd. Euro auf Rentenversicherungsbeiträge für pflegende Angehörige, die derzeit aus Beitragsmitteln finanziert werden. Auch in der GKV werden gesamtgesellschaftliche Lasten von mindestens 20 Milliarden Euro jährlich über Versicherungsbeiträge getragen. Besonders einschneidend wirkt seit Jahren die fehlende Kompensation der Zahlungen für Bürgergeldempfänger in Höhe von rund 9 Milliarden Euro. Der aktuelle Bundeszuschuss von 14,5 Milliarden Euro ist bei weitem nicht kostendeckend. Nach Schätzungen der Betriebskrankenkassen (BKK) wird sich das… 

more »Finanzieller Druck auf Kranken- und Pflegekassen steigt enorm

Seegene und Springer Nature starten das Programm „Nature Awards MDx Impact Grants“

Das von Seegene und Springer Nature ins Leben gerufene Forschungsprogramm „Nature Awards MDx Impact Grants“ – eine neue Initiative zur Entwicklung innovativer diagnostischer Assays – unterstützt Forschende weltweit bei der Entwicklung diagnostischer Tests mit Hilfe der zukunftsweisenden Multiplex-PCR-Technologie von Seegene. Die weltweite Aufforderung zur Einreichung von Forschungsprojekten baut auf dem Erfolg des Open-Innovation-Programms 2023 auf, für das 281 Bewerbungen aus 47 Ländern eingingen, von denen 26 ausgewählt wurden. Mit dem Start der zweiten Phase ermöglichen Seegene und Springer Nature eine noch umfassendere Beteiligung und Innovation und setzen sich weiter für die Verbreitung der Molekulardiagnostik ein. Die Bewerbungsfrist endet am 2. Dezember 2024. Die erste Bewertung wird im Februar 2025 abgeschlossen, gefolgt von einer Vor-Ort-Bewertung und einer finalen Beratung. Die endgültigen Preisträger werden im August 2025 bekannt gegeben, wobei Nature Awards das Einreichungs- und Bewertungsverfahren leitet. Seegene ist für die gesamte… 

more »Seegene und Springer Nature starten das Programm „Nature Awards MDx Impact Grants“